Peking University Cancer Hospital & Institute: Lymphoma trials

The registry lists 14 Lymphoma studies with Peking University Cancer Hospital & Institute as lead sponsor. 5 are open to participants now and 0 have results posted.

Phase 1 3Phase 2 3No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• JWCAR239 in Patients With B Cell Non-Hodgkin LymphomaNot yet recruitingNCT07024147Phase 1
• A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell LymphomaRecruitingNCT07000617Phase 2
• Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell LymphomaNot yet recruitingNCT06757387Phase 1/2
• A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT06313957Phase 1
• Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell LymphomaRecruitingNCT05590221Phase 2
• Head-to-head Comparison Between [18F]-FDG PET/CT and PET/MRI in LymphomasStatus unknownNCT05390632
• The Performance of Multi-tracer Multimodality PET in LymphomaStatus unknownNCT05004961
• Positron Nuclide Labeled NOTA-FAPI PET Study in LymphomaStatus unknownNCT04367948Not applicable
• 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell LymphomaStatus unknownNCT03051581Not applicable
• Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell LymphomaStatus unknownNCT03051568Not applicable
• 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell LymphomaStatus unknownNCT03051555Not applicable
• Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell LymphomaStatus unknownNCT03051542Not applicable
• Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Diffuse Large B-cell LymphomaStatus unknownNCT02931201Not applicable
• 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell LymphomaStatus unknownNCT02928861Not applicable